State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.

IF 2.7 3区医学 Q3 ONCOLOGY Strahlentherapie und Onkologie Pub Date : 2024-10-04 DOI:10.1007/s00066-024-02301-y

Mehrnaz Mostafavi, Farhood Ghazi, Mahboobeh Mehrabifard, Vahid Alivirdiloo, Mobasher Hajiabbasi, Fatemeh Rahimi, Ahmad Mobed, Gholamreza Taheripak, Marzieh Ramezani Farani, Yun Suk Huh, Salar Bakhtiyari, Iraj Alipourfard

{"title":"State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.","authors":"Mehrnaz Mostafavi, Farhood Ghazi, Mahboobeh Mehrabifard, Vahid Alivirdiloo, Mobasher Hajiabbasi, Fatemeh Rahimi, Ahmad Mobed, Gholamreza Taheripak, Marzieh Ramezani Farani, Yun Suk Huh, Salar Bakhtiyari, Iraj Alipourfard","doi":"10.1007/s00066-024-02301-y","DOIUrl":null,"url":null,"abstract":"<p><p>Radiotherapy (RT) is a gold standard cancer treatment worldwide. However, RT has limitations and many side effects. Nanoparticles (NPs) have exclusive properties that allow them to be used in cancer therapy. Consequently, the combination of NP and RT opens up a new frontier in cancer treatment. Among NPs, gold nanoparticles (GNPs) are the most extensively studied and are considered ideal radiosensitizers for radiotherapy due to their unique physicochemical properties and high X‑ray absorption. This review analyzes the various roles of NPs as radiosensitizers in radiotherapy of glioblastoma (GBS), prostate cancer, and breast cancer and summarizes recent advances. Furthermore, the underlying mechanisms of NP radiosensitization, including physical, chemical, and biological mechanisms, are discussed, which may provide new directions for next-generation GNP optimization and clinical transformation.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-024-02301-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Radiotherapy (RT) is a gold standard cancer treatment worldwide. However, RT has limitations and many side effects. Nanoparticles (NPs) have exclusive properties that allow them to be used in cancer therapy. Consequently, the combination of NP and RT opens up a new frontier in cancer treatment. Among NPs, gold nanoparticles (GNPs) are the most extensively studied and are considered ideal radiosensitizers for radiotherapy due to their unique physicochemical properties and high X‑ray absorption. This review analyzes the various roles of NPs as radiosensitizers in radiotherapy of glioblastoma (GBS), prostate cancer, and breast cancer and summarizes recent advances. Furthermore, the underlying mechanisms of NP radiosensitization, including physical, chemical, and biological mechanisms, are discussed, which may provide new directions for next-generation GNP optimization and clinical transformation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米粒子在放射治疗中的最新应用：癌症治疗的协同效应平台。

放疗（RT）是全球治疗癌症的金标准。然而，RT 有其局限性和许多副作用。纳米粒子（NPs）具有独特的特性，可用于癌症治疗。因此，纳米粒子与 RT 的结合开辟了癌症治疗的新领域。在 NPs 中，金纳米粒子（GNPs）的研究最为广泛，由于其独特的物理化学特性和对 X 射线的高吸收率，被认为是放疗的理想放射增敏剂。本综述分析了 NPs 作为放射增敏剂在胶质母细胞瘤（GBS）、前列腺癌和乳腺癌放疗中的各种作用，并总结了最新进展。此外，还讨论了 NP 辐射增敏的基本机制，包括物理、化学和生物机制，这可能会为下一代 GNP 的优化和临床转化提供新的方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Strahlentherapie und Onkologie 医学-核医学

CiteScore

5.70

自引率

12.90%

发文量

141

审稿时长

3-8 weeks

期刊介绍： Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.